Trial Profile
A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 19 May 2015 Results presented at the Digestive Disease Week 2015.
- 14 Oct 2014 Primary endpoint of 'percentage of participants achieving remission quantified as a MAYO score of 2 or less (with no subscore1)' has not been met, according to a GW Pharmaceuticals media release.
- 14 Oct 2014 Preliminary top-line results published in a GW Pharmaceuticals media release.